| Literature DB >> 35855093 |
Elizabeth Tuudah1, Una Foye1, Sara Donetto1, Alan Simpson1.
Abstract
Objective: Adults living with Type 2 diabetes (T2D) and severe mental illness (SMI) disproportionally experience premature mortality and health inequality. Despite this, there is a limited evidence-base and evaluation of non-pharmacological integrated interventions that may contribute to improved patient experience and outcomes. To improve our understanding of how to optimise integrated care for this group, this review evaluates the effectiveness, acceptability, and feasibility of non-pharmacological integrated interventions for adults with SMI and T2D.Entities:
Keywords: Type 2 diabetes; integrated care; integrated interventions; mixed-methods systematic review; severe mental illness
Year: 2022 PMID: 35855093 PMCID: PMC9248983 DOI: 10.5334/ijic.5960
Source DB: PubMed Journal: Int J Integr Care Impact factor: 2.913
Inclusion/exclusion criteria.
|
| ||
|---|---|---|
| INCLUSION CRITERIA | EXCLUSION CRITERIA | |
|
| ||
| Population | Adults aged 18 years and above; diagnosis of SMI as defined by any recognised diagnostic criteria and a diagnosis of T2D which had been diagnosed by a physician or confirmed by participant’s medical records. | Children and adolescence (aged below 18); no diagnosis of SMI; studies only involving participants with type 1 diabetes. |
|
| ||
| Interventions | Non-pharmacological integrated interventions evaluating diabetes-related and psychosocial outcomes (e.g., psychological health interventions, physical health interventions, nutritional health interventions, digital health interventions); qualitative studies that explored experiences and views of the intervention. | Non-pharmacological interventions targeting only T2D or only mental health outcomes; pharmacological interventions; preventative interventions to reduce the risk of developing T2D (e.g., diabetes screening; diabetes risk management interventions; weight loss to reduce diabetes risk); diabetes preventive pharmacotherapy. |
|
| ||
| Comparator | Treatment as usual, an alternative non-pharmacological intervention, no intervention (e.g., waitlist control group), and enhanced usual care. | None. |
|
| ||
| Outcomes/phenomena of interest | Primary outcomes include diabetes knowledge, glycaemic control (HbA1c), diabetes self-efficacy, general health (e.g., weight, BMI), psychiatric illness self-management, mental illness symptom severity and quality of life (QoL) measured by validated and standardised measures; experiences and opinions of the intervention. Secondary outcomes include participant attendance, adverse effects of intervention, adverse events experienced (related and not related to the intervention). | Studies that focused on outcomes only related to diabetes and general health outcomes; outcomes only related to mental health; only medication related outcomes (e.g., dose, compliance). |
|
| ||
| Study Design | Interview studies, observational studies, ethnographic studies, randomised controlled trials, randomised and non-randomised trials, prospective studies, pilot studies, feasibility studies, and case series studies. | Pharmacological studies, conference proceedings, research posters, protocols and review articles were excluded. |
|
| ||
Figure 1PRISMA flow diagram.
Summary of study outcomes.
|
| ||||
|---|---|---|---|---|
|
| ||||
|
| ||||
| STUDY | PRIMARY OUTCOME MEASURES | RESULTS | SECONDARY OUTCOME MEASURES | FINDINGS |
|
| ||||
| Aftab et al., (2018) (1) | Diabetes control | Significant reduction diabetes in control (p = .03) | ||
| General health status | Significant reduction on the mental subscale of the SF-36 from baseline to 60-week follow-up (p = .02) | |||
| Serious mental illness symptoms | No significant reduction in depression or psychopathology | |||
| Functioning | Significant reduction in functioning (p = .037). No significant reduction in disability | |||
|
| ||||
| Chwastiak et al., (2018) (2) | Diabetes control | Improved diabetes control from baseline to 3-month follow-up (p = .049) | ||
| BMI | Reduced BMI from baseline to 3-month follow-up (p = .04) | |||
| Serious mental illness symptoms | No significant changes in measures of psychiatric symptoms | |||
|
| ||||
| McKibbin et al., (2010) (3) | Diabetes control | No significant change in diabetes control | Adverse events | 2 participants did not complete the follow-up assessment due to inpatient hospitalisation |
| Significant reduction on the physical symptoms subscale of the SF-12 from baseline to 16-week follow-up (p = .05). | ||||
| Serious mental illness symptoms | No significant change on the mental health subscale. | |||
| Significant reduction in depression symptoms from baseline to 16-week follow-up (p = .01). No significant change in measures of psychiatric symptom severity | ||||
| Functioning | ||||
|
| ||||
| Sajatovic et al., (2011) (4) | Diabetes control | No significant change in diabetes control | ||
| General health status | No significant change in general health status or BMI | |||
| Serious mental illness symptoms | Significant reduction in depression (p = .01) and psychopathy (p = .01) at 16-week follow-up. No significant change in psychiatric symptom severity | |||
| Functioning | Significant reduction in functioning (p = .01) and no significant reduction in disability (p = .06) | |||
|
| ||||
| Sajatovic et al., (2017) (5) | Diabetes control | No significant change in diabetes control | Adverse events | 119 adverse events among 74 participants. Adverse events occurred among 6 peer educators, 30 participants receiving treatment as usual, and 38 TTIM participants. |
| General health status | No significant change in general health status or BMI | |||
| Serious mental illness symptoms | Significant reduction in psychopathy (p < 001) and depression (p = .016) from baseline to 60-week follow-up. No significant reduction in psychiatric symptom severity. | |||
| Functioning | No significant reduction in disability ratings. Significant reduction in disability from baseline to 60-week follow-up (p = .003) | |||
|
| ||||
|
| ||||
|
| ||||
|
|
|
|
|
|
|
| ||||
| Blixen et al., (2014) (6) | Positive group experience | Delivering the intervention increased peer educators’ confidence and created group cohesiveness | ||
| Success with learning the manual | Peer educators had a positive experience learning the training manual content | |||
| Increased knowledge of T2D/SMI | Peer educators developed a greater understanding of their health conditions | |||
| Improved self-management of T2D/SMI | Becoming a peer educator increased awareness of the importance of effective self-management | |||
| Increased self-confidence | Becoming a peer educator increased confidence in knowing their role and supporting group members | |||
| United in purpose | All group members had the same goal | |||
|
| ||||
| Lawless et al., (2016) (7) | Disseminating health information | Good attendance from study participants | Participant attendance | 80 (80%) participants attended at least one session, 49 (61%) completed all 12 sessions |
| Facilitating group processes | Nurse educators encouraged the development of a therapeutic environment | Adverse events | Peer educators’ illness severity, participants’ symptoms impacting some group interactions | |
| Minimising logistical barriers | Peer educators used effective modelling strategies | |||
| Coordinating interdisciplinary communication | Nurse educators provided care-linkage to enhance communication between participants’ healthcare providers | |||
|
| ||||
Key: BMI = Body Mass Index; TTIM = Targeted Training in Illness Management.
Summary of study and participant characteristics.
|
| |||||
|---|---|---|---|---|---|
| AUTHOR, YEAR, COUNTRY | STUDY DESIGN/METHODS, SAMPLE SIZE | LENGTH OF INTERVENTION | LOCATION | PARTICIPANT CHARACTERISTICS | INTERVENTION CHARACTERISTICS |
|
| |||||
|
| |||||
|
| |||||
| Aftab et al., 2018 (1), USA | Randomised Controlled Trial | 60 weeks | Primary care | Anxiety diagnosis group: Diagnosis: 22.34% with schizophrenia/schizoaffective disorder, 34.04% with bipolar disorder; 43.62% with major depressive disorder Age (M ± SD): 51.78 ± 9.96 Gender: 68.09% Females, 32.81% Males Ethnicity: 51.06% African American, 35.11% Caucasian, 13.83% other HbA1c (M ± SD %): 7.80 ± 2.11 Diagnosis: 26.42% with schizophrenia/schizoaffective disorder, 34.04% with bipolar disorder, 22.64% with major depressive disorder Age (M ± SD): 53.47 ± 8.93 Gender: 60.38% Females; 39.62% Males Ethnicity: 55.66% African American, 38.68% Caucasian, 5.66% other HbA1c (M ± SD %): 8.17 ± 2.38 | Targeted Training in Illness Management (TTIM): A group-based psychosocial treatment focusing on psychoeducation, problem identification, goal setting, behavioural modelling, and care linkage. Sessions co-facilitated by a nurse and a peer-educator covers topics on SMI education, diabetes education, problem solving skills, nutrition, physical activity, medication education, medical and social support, and foot care education. Step 1- 12 weekly in-person group sessions with six to 10 participants per group. Step 2- 48 weeks with telephone maintenance sessions which last from 10 to 15 mins, for the first three months and monthly thereafter. |
|
| |||||
| Chwastiak et al., 2018 (2), | Randomized controlled pilot study | The mean duration of the active treatment was 14.8 weeks, with a range of 9 weeks to 27 weeks. | Community mental health centre |
Diagnosis: 48% with depression, 24% with schizophrenia, 28% with bipolar disorder, all with T2D diagnosis Age (M ± SD): 54 ± 9.4 Gender: 64% Females, 36% Males Ethnicity: 53% African American, 10% Hispanic, 37% White | Adapted collaborative care (based on TEAMcare model): Initial (60-minute) nurse care manager visit for a health assessment and an individualised health plan, then 30-minute visits for the support of chronic illness self-management (including medication adherence, healthy nutrition, and regular physical activity) every other week for 12 weeks and monthly thereafter for up to six months. Nurses used motivational interviewing and behavioural activation to address barriers to self-management and coordinated multi-agency care. |
|
| |||||
| McKibbin et al., 2010 (3), | Randomized pre-test, post-test control group design | 24 weeks | In board-and-care and community clubhouse settings | Usual care + information: Diagnosis (M ± SD): Schizophrenia: 23 ± 88.5, Schizoaffective: 3 ± 11.5, all with T2D diagnosis Gender: 38.5% Females, 61.5% Males Age (M ± SD): 55.6 ± 8.7 Ethnicity (M ± SD): Euro-American: 18 ± 69.2, Other: 8 ± 30.8 Diagnosis (M ± SD): Schizophrenia: 19 ± 73.1, Schizoaffective: 7 ± 26.9, all with T2D diagnosis Gender: 38.5% Females, 61.5% Males Age (M ± SD): 52.4 ± 8.6 Ethnicity (M ± SD): Euro-American: 12 ± 46.2, | |
|
| |||||
| Sajatovic et al., 2011 (4), | Prospective, uncontrolled, case-series pilot trial | 16 weeks | Primary care |
Diagnosis: 25% with schizophrenia, 28% with bipolar disorder, 48% with major depressive disorder, all with T2D diagnosis Age (M ± SD): 52.7 ± 9.5 Gender: 64% Females, 36% Males Ethnicity: 54% African American, 37% Caucasian, 10% Other Use of second-generation antipsychotic medication: 37% HbA1c (M ± SD %): 8.2 ± 2.3 BMI (M ± SD): 36.0 ± 8.7 | Targeted training in illness management (TTIM) (as previously described). |
|
| |||||
| Sajatovic et al., 2017 (5), | Randomised controlled trial | 60 weeks | Primary care |
Diagnosis: all with a diagnosis of TD2 and SMI Age range: 33 to 62 years (median 49.5) Ethnicity: 75% were from a racial ethnic minority group | Targeted training in illness management (TTIM) (as previously described). |
|
| |||||
| Blixen et al., (2014) (6), USA | Phenomenological | Primary care |
Age range: 45 to 64 (median 56) Gender: 5 females; 3 males Ethnicity: 2 White non-Hispanic, 4 Black, non-Hispanic, 2 Hispanic, White. Diagnosis: 5 T2D and depression, 2 T2D and schizophrenia, 1 T2D and bipolar disorder | Targeted training in illness management (TTIM) (as previously described). | |
|
| |||||
| Lawless et al., (2016) (7), USA | Basic interpretation | Primary care |
| Targeted training in illness management (TTIM) (as previously described). | |
|
| |||||
Key: BMI = Body Mass Index; DART = Diabetes Awareness and Rehabilitation Training; HbA1c = Glycated haemoglobin; T2D = Type 2 diabetes; TTIM = Targeted Training in Illness Management.
Figure 2Data synthesis of study findings in meta-aggregation.
QualSyst Tool for assessment of quality of the included studies.
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
|
| ||||||||||||
| AUTHOR | OBJECTIVE AND STUDY DESIGN (1,2) | PARTICIPANT SELECTION AND CHARACTERISTICS (3,4) | RANDOM ALLOCATION AND BLINDING (5,6,7) | OUTCOME (8) | SAMPLE SIZE (9) | ANALYTICAL METHODS (10,11,12,13) | CONCLUSION SUPPORTED BY RESULTS (14) | TOTAL SUM | TOTAL POSSIBLE SUM | SUMMARY SCORE (%) | LIBERAL THRESHOLD (55 ≤ %) | CONSERVATIVE THRESHOLD (75 ≤ %) |
|
| ||||||||||||
| Aftab et al., (2018) (1) | 2 | 4 | 0 | 2 | 1 | 3 | 1 | 13 | 22 | 46 | 0 | 0 |
|
| ||||||||||||
| Chwastiak et al., (2018) (2) | 4 | 3 | 2 | 2 | 2 | 5 | 2 | 19 | 24 | 69 | 1 | 0 |
|
| ||||||||||||
| McKibbin et al., (2010) (3) | 2 | 3 | 0 | 2 | 1 | 4 | 2 | 15 | 22 | 54 | 0 | 0 |
|
| ||||||||||||
| Sajatovic et al., (2011) (4) | 4 | 3 | 2 | 2 | 2 | 4 | 2 | 19 | 24 | 69 | 1 | 0 |
|
| ||||||||||||
| Sajatovic et al., (2017) (5) | 4 | 4 | 2 | 2 | 2 | 3 | 2 | 21 | 28 | 75 | 1 | 1 |
|
| ||||||||||||
|
| ||||||||||||
|
| ||||||||||||
|
|
|
|
|
|
|
|
|
|
| |||
|
| ||||||||||||
| Blixen et al., (2014) (6) | 4 | 4 | 6 | 2 | 16 | 20 | 80 | 1 | 1 | |||
|
| ||||||||||||
| Lawless et al., (2016) (7) | 2 | 4 | 1 | 1 | 8 | 20 | 40 | 0 | 0 | |||
|
| ||||||||||||